StockData

Goldenwell Biotech, Inc. (GWLL) stock

GWLLOTCFood and Kindred ProductsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 4/30
$0.65+0.05 (+8.33%)

Close on Oct 19, 2026Market cap $64.35MP/E –Yield –

Goldenwell Biotech operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Goldenwell Biotech's operating income for the twelve months ending Jun 30, 2026 was -$114.80K. For fiscal 2025 it was -$113.33K. The highest annual figure on record is -$113.33K in fiscal 2025.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$113.33K–
FY2024Dec 31, 2024-$123.10K–
FY2023Dec 31, 2023-$115.83K–
FY2022Dec 31, 2022-$985.11K–
FY2021Dec 31, 2021-$118.27K–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$34.78K–
Q1 FY2026Mar 31, 2026-$31.34K–
Q4 FY2025Dec 31, 2025-$22.90K–
Q3 FY2025Sep 30, 2025-$25.80K–
Q2 FY2025Jun 30, 2025-$28.20K–
Q1 FY2025Mar 31, 2025-$36.44K–
Q4 FY2024Dec 31, 2024-$25.35K–
Q3 FY2024Sep 30, 2024-$20.97K–
Q2 FY2024Jun 30, 2024-$47.82K–
Q1 FY2024Mar 31, 2024-$28.96K–
Q4 FY2023Dec 31, 2023-$20.80K–
Q3 FY2023Sep 30, 2023-$35.41K–
Q2 FY2023Jun 30, 2023-$27.08K–
Q1 FY2023Mar 31, 2023-$33.61K–
Q4 FY2022Dec 31, 2022-$920.33K–
Q3 FY2022Sep 30, 2022-$4.58K–
Q2 FY2022Jun 30, 2022-$26.80K–
Q1 FY2022Mar 31, 2022-$33.39K–
Q4 FY2021Dec 31, 2021-$100.25K–
Q3 FY2021Sep 30, 2021-$88.71K–

More Goldenwell Biotech figures

See a number that looks wrong?